ALN-2232 / Alnylam - LARVOL DELTA

In the second half of 2026, Alnylam expects to announce clinical data from additional pipeline programs... (Businesswire) - "Results from a Phase 1 clinical trial of ALN-2232 in obesity and weight management."

P1 data • Obesity

A Study to Evaluate ALN-2232 in Participants With Obesity (clinicaltrials.gov) - P1/2 | N=156 | Recruiting | Sponsor: Alnylam Pharmaceuticals | Trial primary completion date: Feb 2028 ➔ Apr 2027

Monotherapy • Trial primary completion date • Genetic Disorders • Obesity

In the second half of 2026, Alnylam expects to announce clinical data… (Businesswire) - "Results from a Phase 1 clinical trial of ALN-HTT02 in patients with Huntington's disease; Results from a Phase 1 clinical trial of ALN-2232 in obesity and weight management."

P1 data • CNS Disorders • Huntington's Disease • Obesity